PH

Phoenix Molecular Designs

3 known investors

phoenixmd.ca ↗

Phoenix Molecular Designs develops small-molecule cancer therapeutics targeting RSK, a driver of tumor growth and metastasis. Its lead candidate, PMD-026, is being developed for patients with RSK-driven breast cancer.

Investors · 3

ES

Eshelman Ventures, LLCWilmingtonvia Fred Eshelman · inferred

FL

Flucas VenturesJupiter · $100K – $5Mvia Ashley Flucas · inferred

PA

Pallasite VenturesVancouver · $100K – $1.5M